Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|December 9, 2024
Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS
Author(s)Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.
Advertisement
Mikkael A. Sekeres, MD, professor of medicine, chief, Division of Hematology, Leukemia Section, University of Miami Health System, Sylvester Comprehensive Cancer Center, discusses safety and efficacy results from a phase 1b/2 study (NCT04539236) combining luspatercept-aamt (Reblozyl) and lenalidomide (Revlimid) in patients with lower-risk, non–5q deletion myelodysplastic syndromes. Sekeres and colleagues shared these results in a presentation at the
Advertisement
Related to this article
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5